Physical Activity and Cognitive Function in Older Adults: A Novel Role for GPLD1 (BrainFit)

Pennington Biomedical Research Center

Status

Completed

Conditions

Aging

Cognitive Dysfunction

Treatments

Behavioral: Brain Health Assessments

Study type

Observational

Funder types

Other

Identifiers

NCT04645134

PBRC 2020-050

Details and patient eligibility

About

The investigators are conducting a cross-sectional, observational study to investigate whether plasma GPLD1 concentrations are associated with higher cognitive function and better brain structure and function in two groups of older adults with high or low levels of physical activity.

Full description

This is a cross-sectional, observational study which will enroll up to 28 healthy, older adults (65-85 y, BMI 20-35 kg/m2), and stratify by current self-reported physical activity level (equal inactive vs. equal highly active).

Aim 1: Investigate whether physical activity level is associated with GPLD1.

Aim 2: Investigate whether cognitive function and brain structure/function are associated with GPLD1.

Enrollment

25 patients

Sex

All

Ages

65 to 85 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Ages 65-85 y (inclusive)
Body mass index (BMI) of 20-35 kg/m2 (inclusive)
Willing to have blood and data stored for future research use

Exclusion criteria

History of clinically diagnosed diabetes (Type 1 or 2) or a fasting blood glucose >126 mg/dL
Diagnosed Alzheimer's disease, dementia, or related-brain diseases
Chronic use of atypical antipsychotic or bipolar medications
Initiation of novel pharmacotherapy agents (such as antidepressant, hypertension, or dyslipidemia) within the last 3 months
Uncontrolled hypertension (blood pressure >160 systolic or >110 diastolic)
Asthma that limits the ability to participate in moderate to vigorous physical activity or requiring systemic glucocorticoid administration
Emphysema that limits the ability to participate in moderate to vigorous physical activity or requiring systemic glucocorticoid administration
Current alcohol use exceeding 14 drinks per week in women, exceeding 21 drinks per week in men, having treatment for alcohol abuse in the last year, or having treatment for alcohol abuse more than 1 year ago (but with inability to refrain from alcohol in the past year)
Use of illegal drugs or marijuana within 1-month of completing a Screening Visit; treatment for drug addiction in the 1-year or having treatment for drug addiction >1-year ago, but with an inability to refrain from the drug of addiction in the 1-year
Unwilling to abstain from illegal drugs and marijuana for the duration of the study
Contraindication for MRI (e.g., metal objects, claustrophobia, etc.)
Psychotic mental illness (e.g., schizophrenia, bipolar, on-and- off use of anti-psychotic medication)
History of cardiovascular disease (or diseases of the heart, lungs, or blood) that limits participation in moderate to vigorous physical activity
History of liver, blood, kidney, thyroid or other diseases that limits moderate to vigorous physical activity at the time of enrollment
Cancer that limits moderate to vigorous physical activity
Treatment with systemic immunosuppressant medication
Taking adrenergic stimulants (e.g., amphetamine) or adrenergic blockers (e.g., Propanolol) that will alter metabolic rate
Have plans to substantially alter their current level of physical activity over the next 1-month